Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Maher Khdour, Heba B. Awadallah & Dua’a H. Al-Hamed. (2021) Assessment of treatment satisfaction and adherence amongst diabetic patients in governmental primary care clinic of Ramallah, West-Bank. Hospital Practice 49:1, pages 27-33.
Read now
Read now
LK Billings, M Mocarski, A Basse, B Hunt, WJ Valentine & E Jodar. (2019) Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA. ClinicoEconomics and Outcomes Research 11, pages 271-282.
Read now
Read now
Jodi Strong, Davida Kruger & Lucia Novak. (2017) Insulin glargine 300 units/mL: a guide for healthcare professionals involved in the management of diabetes. Current Medical Research and Opinion 33:4, pages 785-793.
Read now
Read now
Mehul R. Dalal, Mahmood R. Kazemi & Fen Ye. (2017) Hypoglycemia in patients with type 2 diabetes newly initiated on basal insulin in the US in a community setting: impact on treatment discontinuation and hospitalization. Current Medical Research and Opinion 33:2, pages 209-214.
Read now
Read now
William H Polonsky & Robert R Henry. (2016) Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Preference and Adherence 10, pages 1299-1307.
Read now
Read now
David Bruhn, Alan A. Martin, Ruben Tavares, Barnaby Hunt & Richard F. Pollock. (2016) Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US. Journal of Medical Economics 19:7, pages 672-683.
Read now
Read now
Articles from other publishers (41)
Stewart B. Harris & Fleur Levrat‐Guillen. (2023)
Use of the
FreeStyle Libre
system and diabetes treatment progression in
T2DM
: Results from a retrospective cohort study using a
Canadian
private payer claims database
. Diabetes, Obesity and Metabolism 25:6, pages 1704-1713.
Crossref
Crossref
Eugenia Piragine, Davide Petri, Alma Martelli, Vincenzo Calderone & Ersilia Lucenteforte. (2023) Adherence to Oral Antidiabetic Drugs in Patients with Type 2 Diabetes: Systematic Review and Meta-Analysis. Journal of Clinical Medicine 12:5, pages 1981.
Crossref
Crossref
Bruno GuerciRonan RousselFleur Levrat-GuillenBruno Detournay, Eric VicautGérard De PouvourvilleCorinne EmeryJean-Pierre Riveline. (2023) Important Decrease in Hospitalizations for Acute Diabetes Events Following FreeStyle Libre System Initiation in People with Type 2 Diabetes on Basal Insulin Therapy in France. Diabetes Technology & Therapeutics 25:1, pages 20-30.
Crossref
Crossref
Rory J. McCrimmon, Philip Home, Alice Cheng, Francesco Giorgino, Vivian Fonseca, Elisabeth Souhami, Agustina Alvarez, Pascaline Picard & Julio Rosenstock. (2022)
Hypoglycaemia events with
iGlarLixi
versus premix biphasic insulin aspart 30 (
BIAsp
30) in people with type 2 diabetes advancing from basal insulin: An analysis of the
SoliMix
trial
. Diabetes, Obesity and Metabolism 24:12, pages 2391-2399.
Crossref
Crossref
António Lopes, Fátima Roque, Sandra Morgado, Cristina Dinis, Maria Teresa Herdeiro & Manuel Morgado. (2021) Behavioral Sciences in the Optimization of Pharmacological and Non-Pharmacological Therapy for Type 2 Diabetes. Behavioral Sciences 11:11, pages 153.
Crossref
Crossref
Huda Y. Almomani, Carlos Rodriguez Pascual, Sayer I. Al-Azzam & Keivan Ahmadi. (2021) Randomised controlled trial of pharmacist-led patient counselling in controlling hypoglycaemic attacks in older adults with type 2 diabetes mellitus (ROSE-ADAM): A study protocol of the SUGAR intervention. Research in Social and Administrative Pharmacy 17:5, pages 885-893.
Crossref
Crossref
Susan Cornell. (2020) A review of GLP‐1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once‐weekly agents. Journal of Clinical Pharmacy and Therapeutics 45:S1, pages 17-27.
Crossref
Crossref
Sophie C. Payne, Glenn Ward, Richard J. MacIsaac, Tomoko Hyakumura, James B. Fallon & Joel Villalobos. (2020) Differential effects of vagus nerve stimulation strategies on glycemia and pancreatic secretions. Physiological Reports 8:11.
Crossref
Crossref
C. Torre, J. Guerreiro, P. Longo, J. F. Raposo, H. Leufkens & A. P. Martins. (2019) Intensive monitoring of adverse drug events associated with the use of new glucose‐lowering drugs: results from an inception cohort study in Portugal. Diabetic Medicine 37:4, pages 648-656.
Crossref
Crossref
Eyitayo Omolara Owolabi, Daniel Ter Goon & Anthony Idowu Ajayi. (2020) Impact of mobile phone text messaging intervention on adherence among patients with diabetes in a rural setting. Medicine 99:12, pages e18953.
Crossref
Crossref
Sanaz Kamalinia, Robert G. Josse, Patrick J. Donio, Lindsay Leduc, Baiju R. Shah & Sheldon W. Tobe. (2019) Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta‐analysis. Endocrinology, Diabetes & Metabolism 3:1.
Crossref
Crossref
Gilbert Ledesma, Guillermo E. Umpierrez, John E. Morley, Diane Lewis‐D'Agostino, Annett Keller, Thomas Meinicke, Sandra Walt & Maximilian von Eynatten. (2019) Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial. Diabetes, Obesity and Metabolism 21:11, pages 2465-2473.
Crossref
Crossref
Dana Ayoub, Lara Mroueh, Maya El-Hajj, Sanaa Awada, Samar Rachidi, Salam Zein & Amal Al-Hajje. (2019) Evaluation of antidiabetic medication adherence in the Lebanese population: development of the Lebanese Diabetes Medication Adherence Scale. International Journal of Pharmacy Practice 27:5, pages 468-476.
Crossref
Crossref
Carol Baines, Geraldine O’Rourke, Charne Miller, Karen Ford & William McGuiness. (2019) Patient reported experience of blood glucose management when undergoing hyperbaric oxygen treatment. Collegian 26:4, pages 428-434.
Crossref
Crossref
Elena A. Christofides. (2019) Practical Insights Into Improving Adherence to Metformin Therapy in Patients With Type 2 Diabetes. Clinical Diabetes 37:3, pages 234-241.
Crossref
Crossref
Fang L. Zhou, Charlie Nicholls, Lin Xie, Yuexi Wang, Neel Vaidya & Luigi F. Meneghini. (2019) Hypoglycaemia and treatment patterns among insulin‐treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real‐world setting. Endocrinology, Diabetes & Metabolism 2:3.
Crossref
Crossref
Luigi F. Meneghini, Didac Mauricio, Emanuela Orsi, Nebojsa M. Lalic, Anna M.G. Cali, Jukka Westerbacka, Peter Stella, Christophe Candelas, DEA, Valerie Pilorget, Riccardo Perfetti & Kamlesh Khunti. (2019) The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real‐world setting. Diabetes, Obesity and Metabolism 21:6, pages 1429-1436.
Crossref
Crossref
Kai‐Jen Tien, Yi‐Jen Hung, Jung‐Fu Chen, Ching‐Chu Chen, Chih‐Yuan Wang, Chii‐Min Hwu, Yu‐Yao Huang, Pi‐Jung Hsiao, Shih‐Te Tu, Chao‐Hung Wang & Wayne Huey‐Herng Sheu. (2019) Basal insulin therapy: Unmet medical needs in Asia and the new insulin glargine in diabetes treatment. Journal of Diabetes Investigation 10:3, pages 560-570.
Crossref
Crossref
Bruno Guerci, Neha Chanan, Simarjeet Kaur, Juan Guillermo Jasso-Mosqueda & Elisheva Lew. (2019) Lack of Treatment Persistence and Treatment Nonadherence as Barriers to Glycaemic Control in Patients with Type 2 Diabetes. Diabetes Therapy 10:2, pages 437-449.
Crossref
Crossref
Ayman A Al Hayek, Asirvatham A Robert & Mohamed A Al Dawish. (2019) Clinical Characteristics and Satisfaction of Liraglutide Treatment among Patients with Type 2 Diabetes: A Prospective Study. Clinical Medicine Insights: Endocrinology and Diabetes 12, pages 117955141983493.
Crossref
Crossref
Rhea Farhat, Jennifer Assaf, Hicham Jabbour, Hady Licha, Aline Hajj, Souheil Hallit & Lydia Rabbaa Khabbaz. (2019) Adherence to oral glucose lowering drugs, quality of life, treatment satisfaction and illness perception: A cross-sectional study in patients with type 2 diabetes. Saudi Pharmaceutical Journal 27:1, pages 126-132.
Crossref
Crossref
Carla Torre, José Pedro Guerreiro, Sónia Romano, Ana Miranda, Patrícia Longo, Sílvia Alão, João Conceição & Pedro Laires. (2018) Real-world prevalence of mild to moderate hypoglycemic episodes in type 2 diabetes in Portugal: Results from the HIPOS-PHARMA study. Primary Care Diabetes 12:6, pages 537-546.
Crossref
Crossref
Michael Nauck, Atsushi Araki, Uwe Hehnke, Arian Plat, Douglas Clark & Kamlesh Khunti. (2018) Risk of hypoglycaemia in people aged ≥65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus. International Journal of Clinical Practice 72:10, pages e13240.
Crossref
Crossref
Russell Drummond, Samuel Malkin, Michelle Du Preez, Xin Ying Lee & Barnaby Hunt. (2018) The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting. Diabetes, Obesity and Metabolism 20:10, pages 2371-2378.
Crossref
Crossref
Michael Dempsey, Michelle Mocarski, Jakob Langer & Barnaby Hunt. (2018) Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared With Insulin Glargine U100 Plus Insulin Aspart in the U.S.. Endocrine Practice 24:9, pages 796-804.
Crossref
Crossref
Jason Gordon, Phil McEwan, Iskandar Idris, Marc Evans & Jorge Puelles. (2018) Treatment choice, medication adherence and glycemic efficacy in people with type 2 diabetes: a UK clinical practice database study. BMJ Open Diabetes Research & Care 6:1, pages e000512.
Crossref
Crossref
Olga Horvat, Jelena Popržen, Ana Tomas, Milica Paut Kusturica, Zdenko Tomić & Ana Sabo. (2018) Factors associated with non-adherence among type 2 diabetic patients in primary care setting in eastern Bosnia and Herzegovina. Primary Care Diabetes 12:2, pages 147-154.
Crossref
Crossref
Kalyani Murthy, Hannah Caldwell, Mary Beth Hodge, Leigh M. Taylor, Violeta Ristic, Neil Minkoff & Josephine M. Norquist. (2017) A Pilot Observational Study of Hypoglycemia: Patient Reporting Using a Web-Based Portal Compared to Paper Surveys. Journal of Diabetes Science and Technology 12:2, pages 543-544.
Crossref
Crossref
Robert Henry, Julio Rosenstock, John F. McCarthy, Ginger Carls, Tom Alessi, John Yee & Michelle Baron. (2018) Treatment satisfaction with ITCA 650, a novel drug-device delivering continuous exenatide, versus twice-daily injections of exenatide in type 2 diabetics using metformin. Diabetes, Obesity and Metabolism 20:3, pages 638-645.
Crossref
Crossref
Abdallah Y. Naser, Qian Wang, Lisa Y. L. Wong, Jenni Ilomaki, J. Simon Bell, Gang Fang, Ian C. K. Wong & Li Wei. (2017) Hospital Admissions due to Dysglycaemia and Prescriptions of Antidiabetic Medications in England and Wales: An Ecological Study. Diabetes Therapy 9:1, pages 153-163.
Crossref
Crossref
Anthony P. Nunes, Kristy Iglay, Larry Radican, Samuel S. Engel, Jing Yang, Michael C. Doherty & David D. Dore. (2017) Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users. Diabetes, Obesity and Metabolism 19:10, pages 1425-1435.
Crossref
Crossref
Dídac Mauricio, Luigi Meneghini, Jochen Seufert, Laura Liao, Hongwei Wang, Liyue Tong, Anna Cali, Peter Stella, Paulo Carita & Kamlesh Khunti. (2017) Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Diabetes, Obesity and Metabolism 19:8, pages 1155-1164.
Crossref
Crossref
Deborah Young-Hyman, Mary de Groot, Felicia Hill-Briggs, Jeffrey S. Gonzalez, Korey Hood & Mark Peyrot. (2016) Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 39:12, pages 2126-2140.
Crossref
Crossref
S. Halimi & S. Dejager. (2016) Des essais randomisés contrôlés aux études observationnelles. Apports, limites et leçons. Réflexions à propos de l’étude ODYSSEE. Médecine des Maladies Métaboliques 10:8, pages 732-740.
Crossref
Crossref
L. A. Leiter, W. T. Cefalu, T. W. A. de Bruin, J. Xu, S. Parikh, E. Johnsson & I. Gause-Nilsson. (2016) Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease. Diabetes, Obesity and Metabolism 18:8, pages 766-774.
Crossref
Crossref
C. Victor Spain, Jonathon J. Wright, Rebecca M. Hahn, Ashley Wivel & Alan A. Martin. (2016) Self-reported Barriers to Adherence and Persistence to Treatment With Injectable Medications for Type 2 Diabetes. Clinical Therapeutics 38:7, pages 1653-1664.e1.
Crossref
Crossref
Ignacio CongetJavier CastanedaGoran PetrovskiBruno GuerciAnne-Sophie RacaultYves ReznikOhad CohenSarah RunzisSimona de PortuRonnie Aronson. (2016) The Impact of Insulin Pump Therapy on Glycemic Profiles in Patients with Type 2 Diabetes: Data from the OpT2mise Study. Diabetes Technology & Therapeutics 18:1, pages 22-28.
Crossref
Crossref
Marcin Czech, Elżbieta Rdzanek, Justyna Pawęska, Olga Adamowicz-Sidor, Maciej Niewada & Michał Jakubczyk. (2015) Drug-related risk of severe hypoglycaemia in observational studies: a systematic review and meta-analysis. BMC Endocrine Disorders 15:1.
Crossref
Crossref
Ester Yeoh & Pratik Choudhary. (2015) Technology to Reduce Hypoglycemia. Journal of Diabetes Science and Technology 9:4, pages 911-916.
Crossref
Crossref
Cristóbal Morales, Guillermo Rodríguez-Munzenmaier, Dunia Marrero, José M. Baeza, Juan M. Martínez-Jiménez & Gloria Barberá. (2015) Evaluación de la satisfacción del paciente diabético con la utilización del glucómetro portátil BGSTAR© mediante el cuestionario SATIGLU. Avances en Diabetología 31:3, pages 120-127.
Crossref
Crossref
Ralph A. DeFronzo, Andrew Lewin, Sanjay PatelDacheng Liu, Renee Kaste, Hans J. Woerle & Uli C. Broedl. (2015) Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin. Diabetes Care 38:3, pages 384-393.
Crossref
Crossref